83 results about "Use insulin" patented technology

A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus.

This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.

This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.

Method and System for providing a signal from an insulin pump, artificial pancreas, or another insulin delivery device as a source of information for improving the accuracy of a continuous glucose sensor (CGS). The effect of using insulin information to enhance sensor accuracy is most prominent at low blood glucose levels, i.e. in the hypoglycemic range, which is critical for any treatment. A system for providing a filtering/state estimation methodology that may be used to determine a glucose state estimate at time t-τ. The estimation may be extrapolated to some future time t and then the extrapolated value is used to extract the blood glucose component. The blood glucose component of the extrapolation and the output of the CGS are weighted and used to estimate the blood glucose level of a subject.

The invention relates to a method for testing bioactivities, in particular to a method for testing the bioactivities of a GLP-1 receptor agonist. Based on the function of the GLP-1 receptor agonist which can promote mouse insulinoma cells (Min-6) to secrete the insulin, the method comprises the steps of: using insulin quantitatively secreted by a mouse/rat insulin kit to improve the precision of determination through a series of condition optimization processes, and testing the absorbency at the wavelength of 450 nm and the reference wavelength of 590 nm to obtain the effect curve that the GLP-1 receptor agonist induces the Min-6 cells to secrete the insulin; and finally testing the bioactivities of the GLP-1 receptor agonist on the basis of the effect curve.

The present invention features methods of modulating primary stem cell differentiation in culture by altering the endogenous activity of an insulin-like growth factor.

The invention provides a method for preparing a multi-layer bio-based vesica capable of releasing insulin, and belongs to the field of functional materials. The method uses a bio-based macro-molecule as a main raw material, and comprises the following steps: respectively modifying sodium alginate (Alg) and chitosan oligosaccharide (CS) by function monomer 3-aminobenzeneboronic acid (APBA) and 3-carboxyphenylboronic acid (CPBA) to synthesize Alg-g-CPBA grafted copolymer and CS-g-CPBA grafted copolymer; preparing a multi-layer bio-based macromolecular microsphere by using insulin pre-embedded silicon dioxide nano-particles as a template by virtue of layer-by-layer self-assembly; adding CaCl2 to enable the Alg layer to perform physical crosslinking so as to improve the microsphere stability; and finally, removing the template to prepare the multi-layer bio-based vesica capable of releasing insulin. The prepared vesica has high stability, unique hollow structure and excellent biocompatibility, and has a covering amount on insulin being 60 percent; and controllable release of insulin can be realized under the stimulating action of glucose with different concentrations, and the release capacity is 80 percent. The vesica has a potential application value in the field of drug loading, controllable release and the like.

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human secreted IGFBP-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted IGFBP-like polypeptides, compositions, and methods of use for such polypeptides including in cancer.

This invention relates in part to synthesizing high value pharmaceutical proteins in transgenic plants by chloroplast expression for pharmaceutical protein production. We use poly(GVGVP), for example, as a fusion protein to enable hyper-expression of insulin and to accomplish rapid one step purification of fusion peptides utilizing the inverse temperature transition properties of this polymer. We also use insulin-CTB fusion protein in chloroplasts of nicotine free edible tobacco (LAMD 605) for oral delivery. This invention includes expression of native cholera toxin B subunit gene as oligomers in transgenic tobacco chloroplasts which may be utilized in connection with large-scale production of purified CTB, as well as an edible vaccine if expressed in an edible plant, as a transmucosal carrier of peptides to which it is fused to enhance mucosal immunity, and/or to induce oral tolerance of the products of these peptides. The present invention also relates in part to recombinant DNA vectors for enhanced expression of human serum albumin, insulin-like growth factor I, and interferon-α 2 and 5, via chloroplast genomes.

A method may include displaying to a user an interface at which the user inputs a fear of hypoglycemia index (FHI), the FHI corresponding to an acceptable probability of a blood glucose level being below a threshold blood glucose level. The method may also include receiving blood glucose data for a person with diabetes (PWD). The method may additionally include calculating a probability of the PWD having a blood glucose level below the threshold blood glucose level based on the variability of the received blood glucose data. The method may also include setting one or more target blood glucose levels to align the probability of the PWD having a blood glucose level below the threshold blood glucose level with the acceptable probability associated with the user input FHI. The method may additionally include delivering insulin, using the insulin delivery device, based on the target blood glucose level.

A rotary insulin pen needle includes a needle shield housing, the top end of the needle protective shell body is welded with a needle protective cap fixing seat, and a needle rotating fixing seat is embedded in the needle protection outer shell body, the top end of the needle protective cap fixing seat is bolted with a protective cap on the needle, and the inner side of the bottom end of the needle protection cap fixing seat is provided with a rotating fixing seat baffle plate, the outer side of the insulin injection needle of the invention is provided with a needle protective outer shell, theinsulin injection needle is telescopic, When an insulin needle is needed, the needle can be protruded by pushing the needle to rotate the holder, At that end of use, the insulin injection needle canbe shrink into the needle protective housing to prevent the needle from bee damaged and deformed, and the needle protective housing is of a combined structure, which is more conducive to the recoveryand reuse of the recover needle, meanwhile, the insulin injection needle after use can be prevented from being pricked to the hand when being treated, and is safer to be treated.

Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.

The present invention is directed toward peptide analogues of insulin (B) chain that are generally derived from peptides comprising residues (9 to 23) of the native (B) chain sequence. The analogues are altered from the native sequence at position (12, 13, 15) and/or (16), and may be additionally altered at position (19) and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.